175+ Biotechs Adopt Veeva Basics to Fast-Track Drug Development
Pleasanton, Calif. – October 07, 2026 -- More than 175 emerging biotechs have adopted Veeva Basics, a suite of pre-configured, pre-validated applications spanning clinical, regulatory, quality, medical, and commercial functions, Veeva Systems (NYSE: VEEV) announced.
Biotechs deploy Veeva Basics applications in weeks instead of months
The pre-configured systems allow high-growth companies to move from startup to commercialization without building internal IT infrastructure or managing complex customizations. Whitehawk Therapeutics, a company with under 40 employees developing antibody-drug conjugates for difficult-to-treat cancers, used the platform to replace paper-based processes. "Veeva Basics redefined how we operate, significantly improving processes across regulatory and quality for greater speed and compliance," said Bryan Ball, chief technology operations officer at Whitehawk Therapeutics.